A complete list of the members of the PGRx-ITP study group appears in the Appendix. received at least one vaccine within the 12 months before the index date. We found no evidence of an increase in ITP following vaccination in the previous 6 or 12 months (adjusted odds ratio for the previous 12 months 1.0, 95% confidence interval 0.7, 1.4). When the 2-month time window was used, higher ORs were observed for all vaccines (OR= 1.3) mainly attributable to the vaccination against diphtheria-tetanus-pertussis-poliomyelitis (OR= 1.5).
Introduction
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts due to increased destruction and impaired platelet production, partially related to the presence of autoantibodies directed towards platelet-membrane antigens. 1 ITP manifestations include various degrees of cutaneous and/or mucosal purpura, life-threatening hemorrhages occur in less than 5% of adult patients. 2 Onset is frequently insidious and low platelet counts often last beyond six months. 3 In adults, the incidence of ITP is around 3.3 per 100,000
person-years. 4, 5 Studies have suggested that immunizations could be involved in the development of autoimmune disorders. 6 This could be due to molecular mimicry, in which antigens of the host are recognized as being similar to antigens of the immunization, thus provoking the development of autoantibodies. 7, 8 Although several population-based studies have described lymphoproliferative disorders, thyroid or liver disease, definite systemic lupus erythematosus (≥4 American College of Rheumatology criteria), 19 and definite antiphospholipid syndrome.
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Patients with isolated positive anti-nuclear antibodies (ANA) (titer > 1/80 using HEP2 line cells) without signs of systemic lupus erythematosus or with isolated positive antiphospholipid antibodies (anticardiolipin antibodies > 40IU as determined by ELISA test, and/or anti-β2 Gp1 antibodies and/or lupus anticoagulant) without history of thrombosis were not excluded. Uncertain diagnoses were reviewed by a board of two independent certified hematologists who were blind to medications and vaccinations. Cases of newly diagnosed ITP were classified as definite, possible or rejected by the board. Cases were classified as definite when a normal platelet count was available within the 12 months preceding the date of ITP diagnosis. In the absence of any available previous platelet count, cases were classified as possible only when thrombocytopenia manifested by an abrupt onset of spontaneous and unusual bleeding manifestations without any prior history of bleeding. Cases revealed by a fortuitous discovery of thrombocytopenia without any bleeding symptoms were rejected and only definite and possible cases were included in the analysis. The recruiting specialist (hematologist/ internist) completed a web-based medical data form for each case recruited.
Centers participating in the PGRx-ITP registry were contacted at least every two months by external research assistants, to audit the completeness of the registry with eligible patients seen in the participating centers between 1 April 2008 and 13 June 2011.
For cases, the index date was the date of the first clinical sign or symptom suggestive of ITP, reported by the recruiting physician. For controls, the index date was the date of consultation with the recruiting general practitioner (GP).
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Control-subjects. 216 GPs from the same regions as the internal medicine/ hematology centers participated in this study. They were randomly selected by region from a national list of GPs in France. The GPs were instructed to recruit the first male and female presenting to their practice within the following age strata: [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] were recruited regardless of the reason for the consultation and independent of any morbidity or exposure criteria. A registry of 10,808 subjects called referents was constituted. All subjects fulfilling the inclusion criteria and not meeting any of the exclusion criteria were identified independently by the research team. Controls were randomly selected from this registry of referents and matched on age (± 2 years), gender, region of residence (northern or southern France), index date (date of first symptoms for the case and date of consultation for the referent, ±2 months) and season of the index date (Spring/Summer (16 February to 14 September) or Fall/Winter (15 September to 15 February)). Matching by season ensured that cases and controls were compared for similar seasons and therefore had similar opportunities to be vaccinated against influenza. Controls were recruited during the same calendar time period as the ITP cases. A maximum of five controls were matched to each case using an iterative matching process with a control being dropped from the pool after matching.
Physicians were requested to complete an electronic medical data form that included medical information on the patient (chronic diseases and comorbidities, medical risk factors, biological data, current prescriptions and prescriptions for the previous two years).
Assessment of vaccination
All participants recruited from the PGRx-ITP registry and the PGRx-GP database provided written informed consent for their GP to provide their prescriptions for the previous two years.
Furthermore, cases and controls agreed to participate in an in-depth, standardized telephone interview covering medical history, behavioral risk factors, and environmental exposures. An identical, detailed questionnaire on the use of medications and vaccines was administered to all cases and controls. It spanned a 2-year timeframe prior to the interview in accordance with PGRx methodology, although only data relating to the year before the index date were used in this study. The interviews of cases and controls were conducted within 45 days of recruitment by trained interviewers from the PGRx Patients Reported Outcomes center. The telephone interviewer was blind to the case/control status of the interviewee. The interview was derived from methodology previously reported and covered 85 separate health conditions listed in a detailed interview guide given to the subjects ahead of the interview. 21 The interview guide contained complete descriptions of medications and all vaccines marketed in France, their brand names, along with corresponding images of packaging.
Vaccinations were included in the analysis if they were reported by the patient. The agreement between patients' reports of drug use and physicians' prescriptions has been described and published elsewhere.
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For some specific vaccinations that were studied for other purposes, confirmation of vaccination was sought. Confirmation of influenza vaccination was requested and obtained from either the patient or his/her GP, for a sample of 40% of cases and controls reporting this vaccination. Confirmation consisted of the vaccine batch number or a document confirming vaccination (for example a prescription and a certificate from the physician).
This study analyzed exposure to all vaccines, as well as specific vaccines when used by at least 5% of controls in the 12 month-time window. Other vaccines were reported by too few patients to be analyzed separately. For example, of the 878 controls included in the study, 10
(1.1%) reported a hepatitis B vaccination and 10 (1.1%) reported a pneumococcal vaccination.
For the analysis of all vaccines in the 12 months before the index date, the minimum detectable odds ratio was 1.58 (based on 198 cases, 5 controls per case, 35% of the study population exposed, 80% power and a two-sided alpha error of 5%).
Assessment of exposure to other potential risk factors for ITP
Additional information collected during the telephone interview included: sociodemographic factors, medications taken and family history of autoimmune disorders. For each patient recruited, the nominated treating GP (for cases) or the recruiting GP (for controls) completed an electronic data form including prescriptions for the previous two years.
Time windows defining exposure to vaccines for ITP
Vaccine exposure was defined as a vaccine shot during one of the time windows defining exposure. Time windows were defined according to assumptions regarding the potential time to development of ITP following vaccination. Time windows of 12 months, 6 months and 2 months before the index date were studied.
Statistical methods
Potential risk factors for ITP were identified as: history of autoimmune disorders in first degree relatives (yes/no/don't know or missing), and use of systemic non-steroidal antiinflammatory drugs (NSAIDs) in the 12 months before the index date (yes/no). These two factors have been associated with thrombocytopenia in the literature. 24, 25 We considered NSAIDs amongst all drugs that have been associated with ITP, as these were commonly used in the study population.
Cases and their matched controls were compared in respect of these potential risk factors using crude matched odds ratios (OR). Cases and controls were also compared in respect of any vaccination, vaccination against influenza and vaccination against DTPP in the 12, 6 and 2 months before the index date using crude and adjusted odds ratios. Adjusted odds ratios controlled for the potential risk factors for ITP listed in the preceding paragraph. Because vaccinations were considered as exposures for ITP in this study, the separate adjusted analyses of influenza and DTPP vaccines also controlled for vaccination with any vaccine other than influenza or DTPP (as applicable), in the 24 months before the index date.
Odds ratios with 95% confidence intervals (CI) were calculated using conditional logistic regression. Statistically significant associations were described for the 5% level. Analyses were performed with SAS software version 9.2 (SAS Institute, Inc. NC, USA), by data managers listed in the Acknowledgements section. All authors had access to primary clinical data.
Results
Among the 28 adult centers approached to participate in the PGRx-ITP registry, 22 (78.6%) agreed to participate and reported cases considered in this study. 20999 GPs were approached to participate in the PGRx-GP registry, 387 (1.8%) agreed to participate, and of these 216 (55.8%) recruited controls included in this study. The flowcharts in Figure 1 describe the recruitment of cases and controls. 198 newly-diagnosed ITP cases were included in the study, and they were matched with 878 controls. Cases and controls were similar in terms of age (mean 49.0 years, standard deviation 18.2 for both cases and controls), sex (119 or 60.1% of cases and 519 or 59.1% of controls were female) and region of residence.
Of the 198 ITP cases included, the majority presented with a platelet count at or below 50 G/L, and at least one hemorrhagic symptom. Hemorrhagic symptoms were largely cutaneous and/or mucosal, only 8 cases (4.0%) suffered from a visceral hemorrhage. The first treatmentline most commonly administered was corticosteroids (159 or 80.3% of cases), followed by intravenous immunoglobulin (100 or 50.5%) and 164 (82.8%) of cases had at least a shortterm response to initial treatment (Table 1) . Table 2 shows that cases and controls were similar for the matching variables age, gender, region of residence, index date and season of the index date. Neither family history of autoimmune disorders nor systemic NSAIDs in the 12 months before the index date showed any statistically significant associations with case/control status in crude analyses.
Overall, 66 cases (33.3%) and 303 controls (34.5%) received a vaccination within 12 months before the index date. Cases and controls were similar in terms of the proportions vaccinated in the 12 months (adjusted OR 1.0, 95% CI 0.7, 1.4), 6 months (adjusted OR 1.1, 95% CI 0.7, 1.7) and 2 months (adjusted OR 1.3 (95% CI 0.7, 2.3) before the index date. For vaccination against influenza, the adjusted odds ratios were 0.7, 95% CI 0.5, 1.1 in the 12 months, 0.9, 95% CI 0.6, 1.6 in the 6 months, 0.9, 95% CI 0.4, 2.1 in the 2 months before the index date.
For vaccination against DTPP, the adjusted odds ratios were 1.4, 95% CI 0.8, 2.4 in the 12 months, 1.3, 95% CI 0.6, 2.7 in the 6 months, 1.5, 95% CI 0.5, 4.5 in the 2 months before the index date (Table 3) .
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Discussion
We report a prospective multicenter case-control study designed to address a potential association between adult ITP and different routinely administered vaccines. We found no evidence that vaccination in general was associated with an observable increase in the incidence of ITP. Similar proportions of cases and controls had been exposed to vaccination in the 12 and 6 months before the index date. When the 2-month time window was used, higher ORs were observed for all vaccines (OR= 1.3) mainly attributable to the vaccination against DTPP (OR= 1.5). However this increase was not statistically significant. The magnitude of the confidence intervals for the individual vaccines showed that the study lacked power to conclude on them and particularly for DTPP. The minimum detectable OR for the 12-month time window was 1.58 and the study could not rule out weaker associations.
Of note, applying a formal test of equivalence to our data would not have yielded a conclusion of equivalence if narrow OR equivalence ranges such as 0.75 to 1.33 or narrower had been considered.
Advantages of this study include the prospective recruitment of incident cases of ITP, the availability of a general practice-based referent population and the standardized and validated methods for the collection of cases, controls and data. As ITP is a rare disease, large-scale studies of ITP patients, such as this study, are few. Between 1 April 2008 and 13 June 2011, 198 cases were recruited by 22 specialist centers across France. ITP was diagnosed according to strict criteria and cases with a previous history of thrombocytopenia were excluded. This ensured that, as far as possible, relationships between vaccinations and ITP were described for incident cases. Specialist centers recruiting cases and general practice settings recruiting referents were widespread throughout France, so the study population was likely to be generalizable to the French population. Referents were found to be representative of French patients presenting to GPs, in terms of their reasons for consultation (comparison with national data, 26 results not shown). In addition, all methods for the collection of cases, controls and data were standardized and validated to reduce the potential for bias.
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The greater exposure to influenza vaccines in the time window of 12 months preceding the index date in the control group was unexpected, and raises the question about a possible In contrast, a case-control study recently reported a potential association between adult ITP and influenza vaccine. 30 The authors reported three cases of possible ITP related to influenza vaccine among a group of 169 adults with newly-diagnosed ITP. They concluded that this vaccine was associated with a four-fold increase in the risk of ITP. However, data regarding the exposure to vaccines were lacking in both the ITP group and in the controls. Moreover, neither the ITP patients' nor the controls' selection criteria were comparable to the ones used in our study. Inpatient controls, for example, were selected among patients admitted to departments of surgery, without mentioning their length of stay in hospital.
A few case reports have described clusters of ITP incidence within families. 24, 31, 32 We found a similar prevalence of family history of autoimmune disorders between ITP cases and is not a risk factor for ITP after immunization in adults.
Our sample size was not sufficient to test the possible association between vaccines against specific antigens rarely used in the general population and ITP. In addition, the number of cases did not permit the analysis of effects in different age groups such as younger adults (only 21 cases and 95 controls were aged 18-24 years). Moreover, our study did not consider the risk associated with immunization in patients with known ITP.
The clinical features of ITP cases at diagnosis were consistent with those described in the literature, which suggests that there was no bias in the selection of patients. In a retrospective case-series study, Frederiksen et al. (1999) Denmark. In keeping with Frederiksen et al, we observed that ITP affected a wide age range, that incidence peaked in middle-age (a median of 50.8 years in our study and 56 years in the Danish study) and that the female to male ratio was 1.5 (1.7 in the Danish study). 4 We observed that visceral hemorrhages were fairly rare (4.0%).
To conclude, our study reports results showing that in an adult population, the exposure to common vaccines is on average not associated with an observable risk of developing ITP.
Further studies should now address whether or not some vaccines may induce a relapse or worsen the course of the disease in patients previously diagnosed with ITP, as already carried out for rheumatoid arthritis and systemic lupus.
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